Proto-Oncogene Proteins c-cbl
"Proto-Oncogene Proteins c-cbl" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proto-oncogene proteins that negatively regulate RECEPTOR PROTEIN-TYROSINE KINASE signaling. It is a UBIQUITIN-PROTEIN LIGASE and the cellular homologue of ONCOGENE PROTEIN V-CBL.
| Descriptor ID |
D050721
|
| MeSH Number(s) |
D08.811.464.938.750.374 D12.776.624.664.700.172
|
| Concept/Terms |
Proto-Oncogene Proteins c-cbl- Proto-Oncogene Proteins c-cbl
- Proto Oncogene Proteins c cbl
- c-cbl, Proto-Oncogene Proteins
- RING Finger Protein 55
- c-cbl Protein
- cbl Proto-Oncogene Protein
- Proto-Oncogene Protein, cbl
- cbl Proto Oncogene Protein
- CBL E3 Ubiquitin Protein Ligase
- c-cbl Proto-Oncogene Protein
- Proto-Oncogene Protein, c-cbl
- c cbl Proto Oncogene Protein
- RNF55 Protein
- Proto-Oncogene Protein c-cbl
- Proto Oncogene Protein c cbl
- c-cbl, Proto-Oncogene Protein
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins c-cbl".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins c-cbl".
This graph shows the total number of publications written about "Proto-Oncogene Proteins c-cbl" by people in this website by year, and whether "Proto-Oncogene Proteins c-cbl" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2000 | 0 | 2 | 2 |
| 2002 | 0 | 3 | 3 |
| 2004 | 0 | 1 | 1 |
| 2007 | 0 | 2 | 2 |
| 2008 | 2 | 0 | 2 |
| 2009 | 1 | 1 | 2 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 1 | 2 |
| 2015 | 2 | 0 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 2 | 0 | 2 |
| 2020 | 1 | 2 | 3 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proto-Oncogene Proteins c-cbl" by people in Profiles.
-
Phase 1 study of azacitidine in combination with quizartinib in patients with FLT3 or CBL mutated MDS and MDS/MPN. Leuk Res. 2024 Jul; 142:107518.
-
Haploinsufficiency of Casitas B-Lineage Lymphoma Augments the Progression of Colon Cancer in the Background of Adenomatous Polyposis Coli Inactivation. Am J Pathol. 2020 03; 190(3):602-613.
-
Roscovitine enhances All-trans retinoic acid (ATRA)-induced leukemia cell differentiation: Novel effects on signaling molecules for a putative Cdk2 inhibitor. Cell Signal. 2020 07; 71:109555.
-
Hematopoietic progenitor kinase 1 down-regulates the oncogenic receptor tyrosine kinase AXL in pancreatic cancer. J Biol Chem. 2020 02 21; 295(8):2348-2358.
-
c-Cbl targets PD-1 in immune cells for proteasomal degradation and modulates colorectal tumor growth. Sci Rep. 2019 12 27; 9(1):20257.
-
c-Cbl: An Important Regulator and a Target in Angiogenesis and Tumorigenesis. Cells. 2019 05 23; 8(5).
-
c-Cbl Expression Correlates with Human Colorectal Cancer Survival and Its Wnt/?-Catenin Suppressor Function Is Regulated by Tyr371 Phosphorylation. Am J Pathol. 2018 08; 188(8):1921-1933.
-
Single Nucleotide Polymorphisms in CBLB, a?Regulator of T-Cell Response, Predict Radiation Pneumonitis and Outcomes After Definitive Radiotherapy for Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2016 07; 17(4):253-262.e5.
-
Independent genomewide screens identify the tumor suppressor VTRNA2-1 as a human epiallele responsive to periconceptional environment. Genome Biol. 2015 Jun 11; 16:118.
-
Clinical whole-genome sequencing in severe early-onset epilepsy reveals new genes and improves molecular diagnosis. Hum Mol Genet. 2014 Jun 15; 23(12):3200-11.